Shandong Lukang Pharmaceutical (600789.SH): The first subject has been enrolled in the phase IIb clinical trial of CMS203 tablets.

Shandong Lukang Pharmaceutical (600789.SH) announced that its innovative chemical drug CMS203 tablets have officially entered the phase IIb clinical trial for the treatment of male erectile dysfunction. The trial will evaluate the effectiveness and safety of different doses of CMS203 tablets in a multicenter, randomized, double-blind, placebo-controlled clinical trial. The first subject has already been enrolled. According to the "Guidelines for the Diagnosis and Treatment of Erectile Dysfunction" (2022), the main oral drugs used for ED treatment are phosphodiesterase type 5 inhibitors (PDE5). Oral PDE5 inhibitors have become the preferred method of treating ED due to their convenience, safety, and effectiveness, and are widely accepted by most patients. The PDE5 drugs currently on the market in China include sildenafil, vardenafil, avanafil, udenafil, and tadalafil. In vitro pharmacology studies have shown that CMS203 has better selectivity and higher efficiency in targeting PDE-5 compared to other drugs. In phase IIa clinical trials and positive drug comparisons, CMS203 tablets have demonstrated good pharmacological activity and significant advantages.